Skip to main content
Clinical Trials/TCTR20240721002
TCTR20240721002
Recruiting
Phase 4

Efficacy of botulinum toxin A for the management of melasma: A split-face, randomized control study

Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand0 sites30 target enrollmentJuly 21, 2024

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Clinical diagnosis of melasma with symmetrical involvement of both malar areas
Sponsor
Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 21, 2024
End Date
July 31, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Eligibility Criteria

Inclusion Criteria

  • 1\. Age more than or equal to 18 years
  • 2\. Clinical diagnosis of melasma with symmetrical involvement of both malar areas
  • 3\. Willingness to comply with the study protocol and follow\-up visits

Exclusion Criteria

  • 1\. Active skin infection or inflammation at the treatment sites
  • 2\. Open wounds at the treatment sites
  • 3\. Known allergy to study medications
  • 4\. Neuromuscular disorders
  • 5\. Uncontrolled acne vulgaris
  • 6\. History of recurrent herpes infection
  • 7\. Use of topical melasma treatments within 1 month or systemic/injectable treatments within 3 months
  • 8\. Facial procedures (laser, dermabrasion, peeling, radiofrequency, micro\-focused ultrasound) within 6 months
  • 9\. Facial botulinum toxin injections within 6 months
  • 10\. pregnancy or lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials